Content about GlaxoSmithKline

April 27, 2012

The Food and Drug Administration has approved a drug made by GlaxoSmithKline for certain cancer patients.

PHILADELPHIA — The Food and Drug Administration has approved a drug made by GlaxoSmithKline for certain cancer patients.

April 25, 2012

GlaxoSmithKline said its offer to buy Human Genome Sciences was "full and fair" Wednesday after HGS turned it down last week, according to published reports.

NEW YORK — GlaxoSmithKline said its offer to buy Human Genome Sciences was "full and fair" Wednesday after HGS turned it down last week, according to published reports.

Reuters reported that GSK's $13-per-share, $2.6 billion offer for HGS would give the former full control of Benlysta (belimumab), the first new drug approved by the Food and Drug Administration for lupus in more than half a century. The two companies developed the drug together under a partnership, and the drug received approval in March 2011.

April 22, 2012

Steve Anderson recalled during Sunday morning’s State of the Association address how when he started as the president and CEO of the National Association of Chain Drug Stores five years ago, people were interested to see what his eyes would discover at NACDS and within community pharmacy that might help make a difference for the future. Anderson said that today he answers that question in the same way he did back then: “Every day my eyes see something fresh in what you do — in the innovative offerings of community pharmacy.”

PALM BEACH, Fla. — Steve Anderson recalled during Sunday morning’s State of the Association address how when he started as the president and CEO of the National Association of Chain Drug Stores five years ago, people were interested to see what his eyes would discover at NACDS and within community pharmacy that might help make a difference for the future. Anderson said that today he answers that question in the same way he did back then: “Every day my eyes see something fresh in what you do — in the innovative offerings of community pharmacy.”

April 3, 2012

Prestige Brands Holdings on Monday announced that it has completed the purchase of the two remaining brands of the 17 brands it agreed to acquire from GlaxoSmithKline; the purchase of Debrox ear wax remover and Gly-Oxide oral rinse completes the transaction.

IRVINGTON, N.Y. — Prestige Brands Holdings on Monday announced that it has completed the purchase of the two remaining brands of the 17 brands it agreed to acquire from GlaxoSmithKline; the purchase of Debrox ear wax remover and Gly-Oxide oral rinse completes the transaction.

For all 17 brands, Prestige paid a total of $660 million in cash plus a customary post-closing inventory adjustment under the original terms of the agreements.

March 30, 2012

Breast cancer patients taking an experimental drug made by Roche subsidiary Genentech lived significantly longer than those taking another drug made by GlaxoSmithKline, according to results of a late-stage clinical trial.

SOUTH SAN FRANCISCO, Calif. — Breast cancer patients taking an experimental drug made by Roche subsidiary Genentech lived significantly longer than those taking another drug made by GlaxoSmithKline, according to results of a late-stage clinical trial.

March 30, 2012

GlaxoSmithKline Consumer Healthcare strongly supported efforts to inform smokers of the impact tobacco use has on the body, as well as effective ways to quit, during a congressional briefing Friday that was sponsored by Reps. Frank Pallone, D-N.J., and Tim Murphy, R-Pa.

PARSIPPANY, N.J. — GlaxoSmithKline Consumer Healthcare strongly supported efforts to inform smokers of the impact tobacco use has on the body, as well as effective ways to quit, during a congressional briefing Friday that was sponsored by Reps. Frank Pallone, D-N.J., and Tim Murphy, R-Pa.

The briefing, entitled "Understanding Smoking Addiction and How to Accelerate Quitting," addressed how to improve the nation's policies and programs to help smokers become tobacco free.

March 26, 2012

Tums has proven to be the Houdini of digestive tablets — surviving all digestive switch products from H2 blockers through proton-pump inhibitors, and still growing.

Tums has proven to be the Houdini of digestive tablets — surviving all digestive switch products from H2 blockers through proton-pump inhibitors, and still growing. For the 12 weeks ended Jan. 12, sales of Tums were up more than 3%, and it still was among the top three antacids.


March 22, 2012

GlaxoSmithKline on Thursday morning presented exactly how technology might improve appropriate patient self-selection before a panel convened by the Food and Drug Administration to explore expanding the prescripton-to-over-the-counter switch paradigm by incorporating technology and/or pharmacy participation in the application process.

SILVER SPRING, Md. — GlaxoSmithKline on Thursday morning presented exactly how technology might improve appropriate patient self-selection before a panel convened by the Food and Drug Administration to explore expanding the prescripton-to-over-the-counter switch paradigm by incorporating technology and/or pharmacy participation in the application process.

March 21, 2012

A Food and Drug Administration expert panel delivered a favorable vote on a cancer drug made by GlaxoSmithKline.

PHILADELPHIA — A Food and Drug Administration expert panel delivered a favorable vote on a cancer drug made by GlaxoSmithKline.

GSK announced that the FDA Oncologic Drugs Advisory Committee voted 11-2 that clinical trial data indicated a favorable risk-benefit profile of the drug Votrient (pazopanib) in patients with advanced soft-tissue sarcoma who have received chemotherapy. The drug is already approved for treating the kidney cancer renal cell carcinoma.

March 21, 2012

The Food and Drug Administration has approved Watson's generic version of a drug used to prevent and treat osteoporosis in post-menopausal women, the company said.

PARSIPPANY, N.J. — The Food and Drug Administration has approved Watson's generic version of a drug used to prevent and treat osteoporosis in post-menopausal women, the company said.

Watson announced the FDA's approval of ibandronate tablets in the 150-mg strength, a generic version of Genentech's Boniva. Watson plans to launch its version in second quarter 2012.

March 9, 2012

In excess of $102 billion. That's the value over-the-counter medicine delivers to the U.S. healthcare system, Consumer Healthcare Products Association leaders shared with attendees of the CHPA Annual Executive Conference held here Friday morning.

BONITA SPRINGS, Fla. — In excess of $102 billion. That's the value over-the-counter medicine delivers to the U.S. healthcare system, Consumer Healthcare Products Association leaders shared with attendees of the CHPA Annual Executive Conference held here Friday morning.

March 8, 2012

Toothpastes that promise to deliver value-added benefits, such as whitening teeth or battling tooth sensitivity, are helping to brighten sales.


Toothpastes that promise to deliver value-added benefits, such as whitening teeth or battling tooth sensitivity, are helping to brighten sales.


According to SymphonyIRI Group, sales of toothpaste increased about 5% for the 52 weeks ended Jan. 22 at food, drug and mass (excluding Walmart). Among the biggest gainers: Crest 3D White and Sensodyne ProNamel.


Looking to further grow sales and bolster market share, manufacturers continue to churn out toothpastes that promise to deliver even greater results.


March 5, 2012

GlaxoSmithKline Consumer Healthcare North America on Monday launched Tums Freshers, a new tablet-size version of Tums that is 40% smaller than regular Tums and includes a cooling flavor for breath freshening.

PARSIPPANY, N.J. — GlaxoSmithKline Consumer Healthcare North America on Monday launched Tums Freshers, a new tablet-size version of Tums that is 40% smaller than regular Tums and includes a cooling flavor for breath freshening.

February 28, 2012

GlaxoSmithKline can sell an authorized generic of its antidepressant drug to Toronto-based drug maker Apotex, a U.S. judge ruled.

NEW YORK — GlaxoSmithKline can sell an authorized generic of its antidepressant drug to Toronto-based drug maker Apotex, a U.S. judge ruled.

According to a Bloomberg Businessweek report, U.S. District Court judge Joe Pisano ruled the agreement was valid.

February 28, 2012

GlaxoSmithKline has recalled nearly 400,000 bottles of a hypertension drug that were distributed in the United States, according to published reports.

NEW YORK — GlaxoSmithKline has recalled nearly 400,000 bottles of a hypertension drug that were distributed in the United States, according to published reports.

Reuters Health reported that GSK was recalling 394,230 bottles of its DynaCirc CR after the drug's manufacturer, Novartis, reported inconsistent packaging practices. The generic drug is manufactured at a Novartis plant in Lincoln, Neb.

No adverse events were reported, GSK was quoted as saying, but the drug maker elected to put forth a recall as a precautionary measure.

February 17, 2012

One of the main plotlines of the big story called the drug industry over the past several years has been the patent cliff, the steady loss of patent protection on blockbuster primary care drugs and subsequent generic competition that has forced many drug companies to find new revenue streams.

One of the main plotlines of the big story called the drug industry over the past several years has been the patent cliff, the steady loss of patent protection on blockbuster primary care drugs and subsequent generic competition that has forced many drug companies to find new revenue streams. Much of this has taken place in the form of a gradual shift to specialty drugs for such conditions as cancers and autoimmune disorders, but recent developments have shown that primary care drugs may still have some steam left in them.


February 2, 2012

Prestige Brands on Tuesday announced that it has completed its previously announced purchase of 15-of-the-17 brands it agreed to acquire from GlaxoSmithKline.

IRVINGTON, N.Y. — Prestige Brands on Tuesday announced that it has completed its previously announced purchase of 15-of-the-17 brands it agreed to acquire from GlaxoSmithKline.

Prestige did not identify the two brand acquisitions not yet completed.

The former GSK brands represent approximately $200 million in annual revenues, which is projected to push Prestige annual revenues above $600 million, Prestige stated in an investor presentation in December.

January 10, 2012

Nicotine replacement therapies designed to help people stop smoking, specifically nicotine patches and nicotine gum, do not appear to be effective in helping smokers quit long-term, even when combined with smoking-cessation counseling, according to a new survey by researchers at Harvard School of Public Health and the University of Massachusetts Boston posted in an advance online edition of Tobacco Control Monday.

BOSTON — Nicotine replacement therapies designed to help people stop smoking, specifically nicotine patches and nicotine gum, do not appear to be effective in helping smokers quit long-term, even when combined with smoking-cessation counseling, according to a new survey by researchers at Harvard School of Public Health and the University of Massachusetts Boston posted in an advance online edition of Tobacco Control Monday.

December 29, 2011

To help its members keep their New Year's resolutions, including weight loss, eating better and quitting smoking, Sam's Club will offer a variety of free in-club health screenings and smoking-cessation consultations.

BENTONVILLE, Ark. — To help its members keep their New Year's resolutions, including weight loss, eating better and quitting smoking, Sam's Club will offer a variety of free in-club health screenings and smoking-cessation consultations.

December 22, 2011

A Swiss drug maker is acquiring the U.S. rights for several GlaxoSmithKline drugs.

ZUG, Switzerland — A Swiss drug maker is acquiring the U.S. rights for several GlaxoSmithKline drugs.

Covis Pharma Sarl announced Thursday that it had acquired the rights to the antibiotic Fortaz (ceftazidime), the antibiotic Zinacef (cefuroxime), the heart arrhythmia drug Lanoxin (digoxin), the antidepressant Parnate (tranylcypromine sulfate) and the gastroesophogeal reflux disease drug Zantac (ranitidine hydrochloride). GSK will retain rights to the drugs outside the United States.

Financial terms of the deal were not disclosed.

December 20, 2011

Prestige on Tuesday acquired 17 over-the-counter brands from GlaxoSmithKline for a total of $660 million in cash.

IRVINGTON, N.Y. — Prestige on Tuesday acquired 17 over-the-counter brands from GlaxoSmithKline for a total of $660 million in cash. Among the brands Prestige acquired are the pain relievers BC, Goody's and Ecotrin brands; digestive brands Beano, Gaviscon, Phazyme, Tagamet and Fiber Choice; and the Sominex sleep aid brand.

December 7, 2011

Prescribers, patients and specialty care centers no longer will be required to enroll in safety monitoring programs for two drugs used to treat low platelet counts, following changes to their risk evaluation and mitigation strategies.

SILVER SPRING, Md. — Prescribers, patients and specialty care centers no longer will be required to enroll in safety monitoring programs for two drugs used to treat low platelet counts, following changes to their risk evaluation and mitigation strategies.

November 17, 2011

GlaxoSmithKline announced the results from the first of eight phase-3 clinical trials that examined the efficacy of albiglutide in the treatment of Type 2 diabetes.

LONDON — GlaxoSmithKline announced the results from the first of eight phase-3 clinical trials that examined the efficacy of albiglutide in the treatment of Type 2 diabetes.

The Harmony 7 trial was a 32-week, head-to-head, open-label, noninferiority study that compared albiglutide, an investigational once weekly glucagon-like peptide-1 agonist, with once-daily liraglutide. According to the results, patients administered GSK's drug saw a 0.78% reduction in HbA1C, while patients administered liraglutide saw a 0.99% reduction in HbA1C.

November 17, 2011

Consumers are gravitating toward "natural" over-the-counter remedies, according to a new Kline report, "Natural OTCs 2011: Impact of Non-Drug Products on the U.S. OTC Market," released Wednesday.

PARSIPPANY, N.J. — Consumers are gravitating toward "natural" over-the-counter remedies, according to a new Kline report, "Natural OTCs 2011: Impact of Non-Drug Products on the U.S. OTC Market," released Wednesday.

While the U.S. traditional nonprescription drugs industry registered an average compound annual growth rate of 2.5% between 2005 and 2010, the market for natural OTC remedies has grown at a CAGR of 5.9% per year from 2009 to 2011, according to the research study.

November 11, 2011

The list of participating companies in the 13th Annual Drug Store News Group Industry Issues conference — which will be held Tuesday, Nov. 29, at the highly prestigious New York Athletic Club — reads like a “who’s who” of pharmacy retailing.

NEW YORK — CVS/pharmacy. Rite Aid. Walgreens. Sam’s Club. Ahold. H-E-B. The Katz Group. Giant Eagle. Good Neighbor. Health Mart. The list of participating companies in the 13th Annual Drug Store News Group Industry Issues conference — which will be held Tuesday, Nov. 29, here at the highly prestigious New York Athletic Club — reads like a “who’s who” of pharmacy retailing.